Early Intravenous Versus Oral Iron Treatment for Iron Deficiency Anemia in Pregnant Women

What this Trial Is About

Researchers are studying pregnant women with iron deficiency anemia to compare two types of iron treatments started in the second trimester. The trial aims to find out if intravenous iron therapy is better than oral iron therapy at improving blood counts, quality of life, and reducing side effects. This is a randomized, controlled study conducted at multiple sites and sponsored by Thomas Jefferson University. Participants with a single pregnancy between 14 and 24 weeks will be randomly assigned to receive either oral iron tablets 325 mg ferrous sulfate twice daily or intravenous iron ferumoxytol, 510 mg given in two doses 3 to 8 days apart. The study evaluates early initiation of these treatments to address iron deficiency anemia during pregnancy. During the study, researchers will monitor changes in hemoglobin levels over 90 days as the main outcome. They will also assess anemia resolution, anemia status at delivery, the need for additional therapy or blood transfusion, quality of life at various time points, adherence to treatment, and newborn outcomes like birth weight and gestational age. Participants will be followed for up to nine months to gather these important health measures.

Early Antenatal Support for Iron Deficiency Anemia